Maintenance toripalimab for high-risk head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether continuing treatment with an immunotherapy drug called toripalimab after standard treatment helps prevent head and neck cancer from coming back. It's for patients with high-risk features who have no remaining cancer after their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer (squamous cell carcinoma) that was first treated with surgery, radiation, or chemotherapy, and no cancer remains after that treatment.
- Your cancer was at a certain high-risk stage (stage 3 or 4) when diagnosed.
- You are between 18 and 70 years old.
- You are physically active and able to take care of yourself (ECOG score of 0 or 1).
- Your major organs (like liver, kidneys, blood cells, and heart) are working well enough for this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
This study tests whether adding an immunotherapy drug (toripalimab) to chemotherapy before surgery can help shrink tumors and improve outcomes for patients with locally advanced head and neck cancer. It aims to see if this combination is better than surgery alone or surgery with chemotherapy.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.